SOVREMENNAYA PEDIATRIYA.2017.3(83):68-74; doi 10.15574/SP.2017.83.68

Kharchenko Yu. P., Zaretskaia A. V., Hudz V. A., Slobodnichenko L. M., Tselukh V. A.
Odessa National Medical University, Ukraine
Odessa Municipal Clinical Infectious Hospital, Ukraine

Objectives. To determine the etiological structure, clinical and laboratory manifestations of infectious mononucleosis caused by various pathogens in children; to improve the effectiveness of treatment.

Material and methods. The clinical and laboratory examination of 370 children with infectious mononucleosis aged one to 12 years was performed, 67 of them, starting from the three year of age, received the antiretroviral medication Erebra for 3 weeks.

Results. The infectious mononucleosis in 52.9±2.6% of cases was caused by the herpes virus associations and only in 34.1% of patients was detected the solely EBV agent. The severity and duration of clinical and laboratory manifestations depend upon the etiologic factor. The EBV infection is manifested by the typical clinical picture of moderate severity with lymphocytosis and monocytosis. The severe course with neutrophilic leukocytosis, lymphopenia and atypical mononuclears is more common in patients with infectious mononucleosis of CMV etiology. The disease caused by herpes viruses associations is characterized by such signs as high fever, tonsillitis, hepatosplenomegaly with lymphocytosis and neutropenia in CBC. The administration of the antiviral medicine Erebra in the therapy of infectious mononucleosis of different etiology and severity leads to decreased severity and shortened duration of clinical symptoms on average by 1.5 to 2 days.

Conclusion. The severity and duration of infectious mononucleosis manifestations in children depend on etiological factors. The antiviral medication Erebra is equally effective in infectious mononucleosis of different etiology in children.

Key words: infectious mononucleosis, herpes viruses, children, antiviral drug Erebra.

References

1. Vashura LV, Savenkova MS. (2014). Gerpes 6-go tipa (epidemiologiya, diagnostika, klinika). Lechaschiy vrach. 11. https://www.lvrach.ru/2014/11/15436088/

2. Borak VP, Romaniuk LB, Kravets NIa, Borak VT. (2016). Do pytannia pro herpetychnu infektsiiu yak aktualnu problemu sohodennia. Aktualnaia ynfektol. 2: 53—58.

3. Ershova IB. (2014). Effektivnost giporamina (Erebra) v lechenii i profilaktike virusnyih zabolevaniy u detey. Zdorove rebenka. 8(59): 110—113.

4. Infektsionnyie bolezni u detey. Uchebnik. (2013). Pod red prof SA Kramareva, AB Nadragi. Kiev, VSI «Meditsina»: 432.

5. Chernousov AD, Egorova NYu, Gusev LN et al. (2005). Infektsionnyiy mononukleoz, assotsiirovannyiy s virusami gerpesa 4, 5, 6 tipov. Detskie infektsii. 3: 6—11.

6. Kramarev SA, Vigovskaya OV. (2016). Innovations in the treatment and prevention of acute respiratory viral infections in children. Sovremennaya pediatriya. 1(73): 75—81.

7. Krasnov VV, Kotlyarova EV, Obryadina AP et al. (2007). Etiopatogeneticheskie osobennosti infektsionnogo mononukleoza u detey. Detskie infektsii. 6; 2: 36—38.

8. Kramarov SA, Vyigovskaya OV, Taradiy NN, Grinevich AI. (2014). Lechenie infektsionnogo mononukleoza u detey. Sovremennaya pediatriya. 4(60): 55—62.

9. Marushko TV. (2013). Nerevmatychni kardyty u ditei. Zdorovia Ukrainy. Tematychnyi nomer. June: 44—46.

10. Herasymov SV, Bielova HA, Pavuk HL et al. (2014). Novi pidkhody do likuvannia hostroi respiratornoi virusnoi infektsii u ditei. Sovremennaya pediatriya. 4(60): 111—114.

11. Lavrenteva IN, Finogenova NA, Mamedova EA et al. (2011). Osobennosti diagnostiki i techeniya gerpeticheskih infektsiy, vyizvannyih virusami Epshteyna—Barr i gerpesa cheloveka 6 tipa pri neytropeniyah u detey rannego vozrasta. Detskie infektsii. 3: 11—14.

12. Koloskova OK, Ivanova LA, Bielashova OV et al. (2015). Osoblyvosti suchasnoho perebihu entsefalitiv u ditei (ohliad klinichnykh vypadkiv). Aktualnaia ynfektol. 2(7): 23—29.

13. Sorokman TV, Popeliuk O-MV, Parfonova IV, Zymahorova NO. (2016). Osoblyvosti urazhennia pechinky pry infektsiinomu mononukleozi v ditei. Aktualna infektolohiia. 2(11): 177—181.

14. Kriuchko TO, Kushnareva TV, Ostapenko VP, Kolenko IO. (2014). Problemni pytannia ambulatornoho vedennia ditei z hostrymy respiratornymy virusnymy infektsiiamy. Sovremennaya pediatriya. 8(64): 65—68.

15. BryilYova LI, Kizhlo LB, Saharova DA, Emelyanova AN et al. (2013). Sindrom infektsionnogo mononukleoza u detey v Zabaykale. VRACh-ASPIRANT. http://vrach-aspirant.ru/articles/infectious_diseases/12566/

16. MelYohina EV, Chugunova OL, Nikolich AD et al. (2013). Techenie infektsii, assotsiirovannoy s virusom gerpesa cheloveka 6-go tipa, u detey. Detskaya bolnitsa. 4: 3—8.

17. Chukaev SA, Rodnaeva OA. (2009). Otsenka spektra antioksidantnoy aktivnosti giporamina in vitro. Byulleten VSNTs SO RAMN. 2: 140—142.

18. Shipulina LD. (2000). Issledovanie antivirusnoy aktivnosti i drugih biologicheskih svoystv giporamina — novogo protivovirusnogo preparata. Trudyi VILAR. Himiya, tehnologiya, meditsina. Moskva: 228—239.

19. Shipulina LD, Vichkanova SA, Fateeva TV, Krutikova NM. (1996). Eksperimentalno-klinicheskoe izuchenie protivovirusnogo preparata giporamina. Materialyi Vtorogo nauchnogo kongressa «Traditsionnaya meditsina: teoreticheskie i prakticheskie aspektyi». Cheboksaryi. Ch1: 107.

20. Nitipong Permpalung, Patompong Ungprasert, Daych Chongnarungsin et al. (2013). A Diagnostic Blind Spot: Acute Infectious Mononucleosis or Acute Retroviral Syndrome. The American Journal of Medicine. 126; 9: 5—6. https://doi.org/10.1016/j.amjmed.2013.03.017; PMid:23968909

21. Ahmed A. (2014). Immunopathology of CMV Co-Infection: Review. MOJ Immunol. 1(3): 00017. https://doi.org/10.15406/moji.2014.01.00017

22. Bao L, Cowan MJ, Dunham K. (2012). Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother. 35(3): 293—298. (PMID:22421947 [PubMed — indexed for MEDLINE] PMCID: PMC3306600 Free PMC Article) doi 10.1097/CJI.0b013e 31824300a2.

23. Gao LW, Xie ZD, Liu YY et al. (2011). Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China. World J Pediatr. 7: 45—49. [PubMed] https://doi.org/10.1007/s12519-011-0244-1

24. Turabelidze G, Kalilani L, Auwaerter PG. (2016). Infectious mononucleosis. BMJ Best Practice; last updated: Feb 22, 2016. [^©BMJ Publishing Group Ltd.]

25. De Paor M, O'Brien K, Fahey T, Smith SM. (2016, Dec). Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011487.pub2

26. Nicholas John Bennett. (2016, Nov 01). Pediatric mononucleosis and Epstein-Barr virus infection. http://emedicine.medscape.com/article/963894overview

27. Lennon P, Crotty M, Fenton JE. (2015). Infectious mononucleosis: clinical review. BMJ. 350: h1825. https://doi.org/10.1136/bmj.h1825; PMCid:PMC4676118 (Published 21 April 2015)

28. Rezk E, Nofal YH, Hamzeh A et al. (2015, Nov). Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004402.pub3

29. Hellwig T, Jude K, Meyer B. (2013). Варианты лечения инфекционного мононуклеоза. Thaddaus Hellwig. US Pharmacist. 38(5): 38—41.

30. Wang Y, Li J, Ren Y, Zhao H. (2013). The levels of liver enzymes and atypical lymphocytes are higher in youth patients with infectious mononucleosis than in preschool children. Clin Mol Hepatol. 19(4): 382—388. https://doi.org/10.3350/cmh.2013.19.4.382; PMid:24459643 PMCid:PMC3894438